Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS
Home/The Filing Wire/Pasithea Therapeutics Corp./ 10-Q

Quarterly Report · 10-Q

Pasithea Therapeutics Corp.

KTTANASDAQEQUITYCurrent

Quarterly Report

Filed Aug 14, 2026Accepted Aug 14, 2026, 4:30 PM EDTCIK 1841330Accession 0001213900-26-090146
View company →Permanent SEC source ↗
Share

Company context

Pasithea is a clinical-stage biotechnology company primarily focused on the research and development of its lead drug candidate, PAS-004, a next-generation macrocyclic MEK inhibitor intended for the treatment of RASopathies, MAPK pathway-driven tumors, and other diseases. The Company is currently testing PAS-004 in a Phase 1 clinical trial in patients with advanced cancer (NCT06299839), and a Phase 1/1b clinical trial in patients with neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas with symptomatic and inoperable, incompletely resected, or recurrent PN (NCT06961565).

Current securities

KTTANASDAQ · EQUITY · Current
Historical securities (1)
KTTAWNASDAQ · WARRANT · Historical · closed Sep 16, 2026

Recent company filings

  1. Other EventsSep 16, 2026
  2. Submission of Matters to a Vote of Security HoldersSep 9, 2026
  3. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of ListingAug 21, 2026
  4. SCHEDULE 13G/A - filed by Vivo Opportunity Fund Holdings, L.P. regarding Pasithea Therapeutics Corp.Aug 14, 2026
  5. ARS filingAug 7, 2026

Registered securities in this filing

PASITHEA THERAPEUTICS CORP. · 10-Q · Filed 2026-08-14

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock, par value $0.0001 per share

Symbol
KTTA
Exchange
NASDAQ
Classification
COMMON
Status
Current
Filing context

Context: cref_1934038466

Dimensions: us-gaap:StatementClassOfStockAxis

Warrants, to purchase shares of Common Stock, par value $0.0001 per share

Symbol
KTTAW
Exchange
NASDAQ
Classification
WARRANT
Status
Historical · closed Sep 16, 2026
Filing context

Context: cref_388780701

Dimensions: us-gaap:StatementClassOfStockAxis

Accession 000121390026090146 · 2 registered-security cover members

Read the exact SEC filing ↗

As-filed source

Primary evidence
As filedOpen full document ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.